Agent Optimization: ADME, Dose, Decay.

Targeted radiation therapy (TRT) is undergoing another renaissance attributable to U.S. Food and Drug Administration approvals of 223RaCl2 (Xofigo; Bayer) and 177Lu-DOTATATE (Lutathera; Advanced Accelerator Applications) in 2013 and 2018, respectively. The former, though not a TRT agent, exploits